Efficient Drug Development

Oleolive is a pre-clinical biotechnology company with a mission to grow innovative technology from overlooked places to attack tough therapeutic indications.

Our Approach

Oleolive was founded by scientists with a desire to move “technology under rocks” forward from traditionally overlooked research institutions. We do this by pairing our team of deep subject matter experts with institutional researchers to put therapeutics and medical technologies on a path toward commercialization.

Our Focus Areas

  • We are targeting neurodegenerative diseases through multiple mechanisms including neuroinflammation and neurometabolism. We believe a combination of these approaches can affect the pathogenesis of Alzheimer’s Disease and Related Dementias and not just treat symptoms, but result in disease modifying therapies.

  • Our company has multiple repurposed drugs for the treatment of cancers, including pancreatic cancer, triple negative breast cancer and brain cancer such as glioblastoma multiforme. Targets for these drugs include the oncogenic receptor c-Met, lysosome trafficking (facilitating invasion and metastasis), cancer stem cells and the extracellular matrix - tumor cell interaction.

  • Our team is developing a stable platelet-rich plasma product to improve options currently available to aid in hemostasis in austere environments. Our lead technology in this field is in late preclinical testing with pivotal data soon to be acquired.

  • At the end of the day, most medical technologies are developed to extend life, but few target aging as a disease in itself. In addition to identifying natural compounds that contribute to healthy aging, we also have an interest in fibrosis. This disease is a contributing factor to age related diseases and we are developing drugs that block key signaling pathways impacting the fibrotic process.

Our Story

Oleolive was launched based on the research of Dr. Khalid El Sayed a Professor at the University of Louisiana in Monroe who is the inventor of the first technology we licensed. This technology, still a key component of our business model today, is the patented method of extracting and purifying Extra Virgin Olive Oil phenolic compounds such as Oleocanthal. We now produce and sell on Amazon a commercial product named Oligen which contributes to our goal of producing natural supplements that promote healthy aging and longevity. We are also developing additional products to promote a healthy lifestyle.

We have evolved into a late state preclinical biotechnology company with multiple assets being developed to treat a range of medical indications. Our research has been funded by 8 SBIR/STTR grant awards from the National Cancer Institute, the National Heart, Lung and Blood Institute, the Department of Defense, and the National Institute on Aging.